HIV vaccines polytope - Bavarian Nordic/VaxOnco

Drug Profile

HIV vaccines polytope - Bavarian Nordic/VaxOnco

Alternative Names: EP 1232; EP 1233; EP-1232 + EP-1233; HIV DNA vaccine + MVA HIV vaccine - Bavarian Nordic; MVA-BN Polytope; MVA-BN32; MVA-mBN32

Latest Information Update: 20 Apr 2012

Price : $50

At a glance

  • Originator Bavarian Nordic; Pharmexa-Epimmune
  • Developer Bavarian Nordic; VaxOnco
  • Class AIDS vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued HIV-1 infections

Most Recent Events

  • 20 Apr 2012 Discontinued - Phase-I for HIV-1 infections in Germany (Parenteral)
  • 20 Apr 2012 Discontinued - Phase-I for HIV-1 infections in USA (Parenteral)
  • 20 Apr 2012 Discontinued - Phase-I/II for HIV-1 infections in Germany (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top